Without being an expert on such deals, I can't really see that taking Colorectal into Japan in partnership with an established player, very likely one of the big Japanese ppharmas as MAC suggests, would involve major outlay by PEB. Yes, some form of cash/milestone payments like the deal with Cellmid but it ought to be pretty much self-supporting and revenue-positive - no need for armies of salespeople or big promotional costs or special labs, provided they find the right partner.